Days Speakers Session Type Search
Type

    12:45 - 13:45 
    Pituitary: The New & the Old
    Sandoz
    Syndicate 1 & 2
    Pituitary: The New & the Old
    Nelson’s syndrome
    Birmingham, UK
    Pituitary: The New & the Old
    BRAF inhibitors in Papillary Craniopharyngiomas
    Pituitary: The New & the Old
    Checkpoint inhibitor related hypophysitis
    Leeds Teaching Hospitals NHS Trust, Leeds, UK
    Pituitary: The New & the Old
    Panel Discussion and Q&A
    12:45 - 13:45 
    Neuroendocrine tumours for the general endocrinologist
    Advanced Accelerator Applications
    Syndicate 3 & 4
    Neuroendocrine tumours for the general endocrinologist
    Welcome & Introduction
    London, UK
    Neuroendocrine tumours for the general endocrinologist
    Overview & management of NETS
    London, UK
    Neuroendocrine tumours for the general endocrinologist
    Q&A
    Neuroendocrine tumours for the general endocrinologist
    GEP-NETs and PRRT
    Sheffield, UK
    Neuroendocrine tumours for the general endocrinologist
    Q&A
    12:45 - 13:55 
    Oral Poster Presentations
    SfE Theatre
    16:45 - 17:05 
    SfE Connect
    SfE Theatre
    17:05 - 17:35 
    Membership of the European Society of Endocrinology - How can it benefit you?
    European Society of Endocrinology
    SfE Theatre
    Chair: Helen Gregson
    Theatre 1

    10:30 - 11:05 
    Pfizer-Sponsored Presentation
    SfE Theatre
    12:40 - 13:25 
    David Anderson Book Launch
    SfE Theatre
    13:25 - 14:40 
    Oral Poster Presentations
    SfE Theatre
    13:35 - 14:35 
    ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
    Pfizer
    Syndicate 1 & 2
    ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
    A brief history of ACROSTUDY
    Erasmus University MC, The Netherlands
    ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
    Key outcomes: exploring safety and treatment outcomes
    Sheffield, UK
    ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
    Impact of treatment on glucose metabolism
    Sheffield, UK
    ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
    Q&A
    13:35 - 14:35 
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    HRA Pharma Rare Diseases-sponsored
    Syndicate 3 & 4
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    Starting a movement in Cushing’s syndrome
    Oxford University Hospital, United Kingdom
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    The patient journey in Cushing’s syndrome: Can we change the route to a new destination?
    Cardiff & Bristol, UK
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    Getting it right first time: Harnessing experience and expertise to improve outcomes
    Sheffield, UK
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    From the first step: Designing management strategies for the future
    London, UK
    Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
    Collective thinking: How we can build Cushing’s syndrome management strategies with confidence
    Oxford University Hospital, United Kingdom
    16:15 - 16:45 
    Advanced Practice in Endocrinology Nursing Book Launch
    SfE Theatre
    Dr Sofia Llahana
    16:45 - 17:15 
    MTEditor Q&A session
    SfE Theatre

    10:20 - 10:50 
    Pfizer-Sponsored Presentation
    SfE Theatre
    13:10 - 14:15 
    Oral Poster Presentations
    SfE Theatre
    13:20 - 14:20 
    Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
    Bristol-Myers Squibb
    Syndicate 1 & 2
    Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
    The cancer treatment landscape: Current status of immunotherapies and a practical guide to immune-related endocrinopathies
    Liverpool and Sheffield, UK
    Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
    Examples from the clinic and Q&A
    Liverpool and Sheffield, UK
Maralyn Druce
London, UK
Mon 11 12:50
Neuroendocrine tumours for the general endocrinologist
Overview & management of NETS
London, UK
Joan Grieve
London, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
From the first step: Designing management strategies for the future
London, UK
Professor Ashley Grossman
London, UK
Mon 11 12:45
Neuroendocrine tumours for the general endocrinologist
Welcome & Introduction
London, UK
 Higham
Liverpool and Sheffield, UK
Wed 13 13:20
Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
The cancer treatment landscape: Current status of immunotherapies and a practical guide to immune-related endocrinopathies
Liverpool and Sheffield, UK
Wed 13 13:40
Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
Examples from the clinic and Q&A
Liverpool and Sheffield, UK
Niki Karavitaki
Birmingham, UK
Mon 11 12:45
Pituitary: The New & the Old
Nelson’s syndrome
Birmingham, UK
Dr Alia Munir
Sheffield, UK
Mon 11 13:15
Neuroendocrine tumours for the general endocrinologist
GEP-NETs and PRRT
Sheffield, UK
Robert Murray
Leeds Teaching Hospitals NHS Trust, Leeds, UK
Mon 11 13:15
Pituitary: The New & the Old
Checkpoint inhibitor related hypophysitis
Leeds Teaching Hospitals NHS Trust, Leeds, UK
John Newell-Price
Sheffield, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Getting it right first time: Harnessing experience and expertise to improve outcomes
Sheffield, UK
Menai Owen-Jones
Cardiff & Bristol, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
The patient journey in Cushing’s syndrome: Can we change the route to a new destination?
Cardiff & Bristol, UK
Professor Ross
Sheffield, UK
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Key outcomes: exploring safety and treatment outcomes
Sheffield, UK
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Impact of treatment on glucose metabolism
Sheffield, UK
All speakers
Mon 11 13:30
Pituitary: The New & the Old
Panel Discussion and Q&A
Speaker TBC
Mon 11 13:00
Pituitary: The New & the Old
BRAF inhibitors in Papillary Craniopharyngiomas
Professor AJ van der Lely
Erasmus University MC, The Netherlands
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
A brief history of ACROSTUDY
Erasmus University MC, The Netherlands
Professor John Wass
Oxford University Hospital, United Kingdom
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Starting a movement in Cushing’s syndrome
Oxford University Hospital, United Kingdom
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Collective thinking: How we can build Cushing’s syndrome management strategies with confidence
Oxford University Hospital, United Kingdom
Workshop 0
Oral 1
Mon 11 12:45
Oral Poster Presentations
SfE Theatre
Expert 0
Plenary 0
Catering and Social 0
Nurse 0
Other 3
Mon 11 16:45
SfE Connect
SfE Theatre
Tue 12 10:30
Pfizer-Sponsored Presentation
SfE Theatre
Tue 12 12:40
David Anderson Book Launch
SfE Theatre
Symposium 5
Mon 11 12:45
Pituitary: The New & the Old
Sandoz
Syndicate 1 & 2
Mon 11 12:45
Pituitary: The New & the Old
Nelson’s syndrome
Birmingham, UK
Mon 11 13:00
Pituitary: The New & the Old
BRAF inhibitors in Papillary Craniopharyngiomas
Mon 11 13:15
Pituitary: The New & the Old
Checkpoint inhibitor related hypophysitis
Leeds Teaching Hospitals NHS Trust, Leeds, UK
Mon 11 13:30
Pituitary: The New & the Old
Panel Discussion and Q&A
Mon 11 12:45
Neuroendocrine tumours for the general endocrinologist
Advanced Accelerator Applications
Syndicate 3 & 4
Mon 11 12:45
Neuroendocrine tumours for the general endocrinologist
Welcome & Introduction
London, UK
Mon 11 12:50
Neuroendocrine tumours for the general endocrinologist
Overview & management of NETS
London, UK
Mon 11 13:10
Neuroendocrine tumours for the general endocrinologist
Q&A
Mon 11 13:15
Neuroendocrine tumours for the general endocrinologist
GEP-NETs and PRRT
Sheffield, UK
Mon 11 13:35
Neuroendocrine tumours for the general endocrinologist
Q&A
Tue 12 13:35
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Pfizer
Syndicate 1 & 2
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
A brief history of ACROSTUDY
Erasmus University MC, The Netherlands
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Key outcomes: exploring safety and treatment outcomes
Sheffield, UK
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Impact of treatment on glucose metabolism
Sheffield, UK
Tue 12
ACROSTUDY™: Over a decade of real world data recording the treatment of acromegaly with pegvisomant – what have we learned?
Q&A
Tue 12 13:35
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
HRA Pharma Rare Diseases-sponsored
Syndicate 3 & 4
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Starting a movement in Cushing’s syndrome
Oxford University Hospital, United Kingdom
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
The patient journey in Cushing’s syndrome: Can we change the route to a new destination?
Cardiff & Bristol, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Getting it right first time: Harnessing experience and expertise to improve outcomes
Sheffield, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
From the first step: Designing management strategies for the future
London, UK
Tue 12
Collective thinking: Can greater collaboration improve outcomes in Cushing’s syndrome?
Collective thinking: How we can build Cushing’s syndrome management strategies with confidence
Oxford University Hospital, United Kingdom
Wed 13 13:20
Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
Bristol-Myers Squibb
Syndicate 1 & 2
Wed 13 13:20
Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
The cancer treatment landscape: Current status of immunotherapies and a practical guide to immune-related endocrinopathies
Liverpool and Sheffield, UK
Wed 13 13:40
Immunotherapy-related endocrinopathies during cancer treatment: Conquering the hidden threat
Examples from the clinic and Q&A
Liverpool and Sheffield, UK
No Session Type 6
Mon 11 17:05
Membership of the European Society of Endocrinology - How can it benefit you?
European Society of Endocrinology
SfE Theatre
Chair: Helen Gregson
Theatre 1
Tue 12 13:25
Oral Poster Presentations
SfE Theatre
Tue 12 16:15
Advanced Practice in Endocrinology Nursing Book Launch
SfE Theatre
Dr Sofia Llahana
Tue 12 16:45
MTEditor Q&A session
SfE Theatre
Wed 13 10:20
Pfizer-Sponsored Presentation
SfE Theatre
Wed 13 13:10
Oral Poster Presentations
SfE Theatre

0 result(s) found.

Please wait...

     
      - 
     
     
     


    Abstracts from this event
      Abstracts from other events


          Session starts at:
          Abstract time:
        Event:


        Read full abstract